Published online Dec 18, 2023. doi: 10.13105/wjma.v11.i7.351
Peer-review started: September 10, 2023
First decision: September 29, 2023
Revised: October 4, 2023
Accepted: October 23, 2023
Article in press: October 23, 2023
Published online: December 18, 2023
Processing time: 97 Days and 5.2 Hours
The study details the significance of Sodium Polystyrene Sulfonate (SPS) in managing hyperkalemia, a life-threatening condition. SPS, used to remove excess potassium, has side effects, including severe gastrointestinal complications. The exact mechanism of SPS-induced colitis is unclear, but it primarily affects the colon, requiring biopsy for diagnosis.
Comprehensive understanding of the SPS therapy and colitis relationship is crucial for patient safety. This research addresses knowledge gaps, aiming to contribute to future studies in drug safety and gastroenterology.
This study's main goal is to systematically review cases of SPS-induced colitis to understand its prognosis and influencing factors. Achieving these objectives enhances awareness of risks tied to SPS therapy, aiding clinical decisions for hyperkalemia management and guiding future research on risk mitigation.
This systematic review followed the PRISMA guidelines for transparency and methodological rigor. A comprehensive search strategy covered multiple databases and utilized manual searches. Inclusion criteria prioritized case reports or case series studies, with language inclusion restricted to English, Spanish, French, or Portuguese. A two-step screening process and data extraction by independent reviewers ensured rigorous analysis. Methodological quality assessment employed a modified tool, addressing specific aspects related to polystyrene-induced colitis. Data were analyzed using descriptive statistics, providing a comprehensive dataset characterization.
The review examined 442 references, including 51 which comprised 59 cases meeting the criteria. The majority of cases were from the United States (48.2%). The patients age varied from less than 1 year to 89 years and were predominantly diagnosed with SPS-induced colitis. Common symptoms included abdominal pain, bloating, and gastrointestinal issues, with chronic kidney disease being prevalent. Diagnostic procedures such as colonoscopy and biopsies were frequently conducted. Surgical intervention was necessary for 50% of patients, and most had favorable outcomes, with a mean time to symptom resolution of 36.7 days.
This systematic review underscores the importance of monitoring adverse events related to SPS in hyperkalemia treatment. It differentiates mild from severe side effects, advocating for alternative hyperkalemia management, especially for older or fragile patients due to higher associated mortality. The exact mechanisms remain unclear, but factors such as renin concentration and water affinity are implicated.
Future research should prioritize randomized controlled trials to assess SPS use, considering its effectiveness and risks. Alternative hyperkalemia management methods and cautious SPS prescription are crucial, with a focus on addressing knowledge gaps for informed clinical decisions.